Dyno Therapeutics creates novel adeno-associated virus (AAV) vectors that enable safe, efficient and targeted in vivo delivery for revolutionary gene and genome editing therapies. Our data-driven approach combines next-generation DNA synthesis of millions of AAV capsids with high-throughput sequencing and machine learning. We’re systematically mapping the relationship between capsid sequence and function to optimize AAV capsids for improved therapeutic efficacy, in partnership with clinical and preclinical stage companies.

Contact Dyno Therapeutics
eric.kelsic@dyno-tx.com
Visit Website